On 9 April, the College published a flowchart to help veterinary professionals to decide whether or not to carry out a particular type of work, whilst ensuring the health of their teams and clients, and working to uphold animal health and welfare.
The flowchart has been updated as follows:
Firstly, the box that previously said:
‘Can you effectively support the case while maintaining social distancing for your team and the public?’
now says:
‘Can you effectively support the case while abiding by the appropriate social/physical distancing guidance for workplaces to protect your team and the public?’
The College says this new wording better reflects the different language and varying guidance in place across devolved nations. It also recognises that the new government guidance is not just about maintaining a 2m distance, for which ‘social distancing’ appears to become a shorthand, but accepts that other biosecurity measures might be appropriate if the 2m rule cannot be followed in the workplace.
Secondly, the box that previously said:
‘Could the planned intervention have animal health and welfare or public health implications if not carried out within two months?’
‘Could the planned intervention have animal health and welfare or public health implications if not carried out?’
This change recognises that this phase of lockdown-exit may carry on for longer than a two-month period; it therefore leaves it to the clinician’s professional judgement in terms of the implications versus the risk, rather than seeing it within a specific time-period.
RCVS President Niall Connell said: "I’m grateful to the members of our Covid-19 Taskforce for continuing to keep under review our key guidance to the profession during the ongoing pandemic. Whilst these latest changes do not represent any significant changes for vets and vet nurses as they continue to care for the nation’s animals, it is important that we continually keep our guidance in line with that of the UK’s governments."
The updated flowchart is available to view and download from www.rcvs.org.uk/coronavirus.
In next year's election, there are two places on Council for elected veterinary nurses, with successful candidates serving three year terms.
The nomination period runs until 5pm on Friday 31 January 2020. In order to stand, candidates need to complete a nomination form, submit a short biography and personal statement and supply a high resolution digital photo.
Each candidate also needs to have two nominators who need to be veterinary nurses who are on the RCVS Register but are not current RCVS Council members.
The College says nominations will be particularly welcome for VN Council as, due to governance changes, no election took place in 2018 and there was also no election in 2019, because only two candidates stood for the two available places.
Racheal Marshall, Chair of VN Council, said: "Although we are delighted with the two VN Council members who came on board this year, I think all would agree that it was a shame that there was no opportunity for the profession to exercise their democratic right and cast a vote for their preferred candidates.
"Being a member of VN Council and, latterly, its Chair has been a professional highlight for me – I have helped shape recommendations for how we can take the profession forward through the VN Futures project, have played a part in developing the postgraduate Certificates in Advanced Veterinary Nursing and have welcomed many new veterinary nurses to the Register by taking them through their professional declarations.
"We know that veterinary nurses sometimes feel that they struggle to be seen and heard – being a member of VN Council who can shape policy on education and professional conduct and attend events as an ambassador for the profession all helps give veterinary nursing the voice it deserves. So please consider standing for VN Council and I am very happy to talk to people about what it involves and how to fit it around your work and life."
Veterinary nurses who wish to find out more about becoming a candidate for VN Council can arrange an informal conversation with Racheal by contacting Annette Amato, VN Council Secretary, on a.amato@rcvs.org.uk
Eleanor Ferguson, RCVS Registrar and Returning Officer said: "As always, we would encourage those who are interested in having their say in some of the key debates in the regulatory sphere, such as our under care review, our policies around the impact of Brexit and our vision for new veterinary legislation, to become a candidate.
"RCVS Council is at its best when it encompasses a broad range of perspectives, experiences and knowledge, and so we encourage people from all areas of veterinary life and all levels of experience to put themselves forward and share their expertise and insight."
Nomination forms, guidance notes and frequently asked questions for prospective RCVS VN Council candidates can be found at www.rcvs.org.uk/vncouncil20.
Prospective candidates for Council are welcome to contact the Registrar, Eleanor Ferguson (e.ferguson@rcvs.org.uk) and the RCVS CEO, Lizzie Lockett (l.lockett@rcvs.org.uk) for more information about the role of the College and/or Council.
RCVS Council will also be holding its next public meeting on Thursday 23 January 2020, prior to the closure date for Council candidate nominations. Prospective candidates are welcome to attend the Council meeting as an observer. Contact Dawn Wiggins, RCVS Council Secretary, on d.wiggins@rcvs.org.uk if you wish to attend.
Royal Canin highlights that obesity is one of the most common diseases that veterinary professionals face, and impacts patients' quality of life1, as well as their life expectancy2,3. Compliance is a common challenge in weight loss and even those that successfully reach their ideal weight frequently regain weight later. It therefore makes sense, says the company, to focus on prevention as well as long term management for obese cats and dogs.
Caroline Burke, Royal Canin UK Weight Management Specialist said: "Obesity is one of the most common diseases that vets and nurses see in practice, and this webinar is the latest in our programme of education around weight management. Vets and nurses will have the opportunity to learn about how they can help prevent, as well as manage obesity in practice, allowing them to truly make a difference to the lives of their patients."
Alex added: "Obesity is an ever-growing issue for cats and dogs, understanding the risks and prevention techniques is paramount for both pet owners and industry experts.
"This webinar aims to suggest how a lifelong practice monitoring programme can be implemented for the prevention of obesity. Whilst also reviewing the outcomes of weight management and defining types of prevention techniques which can be implemented."
To register for the webinar, 'How to be proactive rather than reactive for effective, preventative obesity management’, visit: https://vetportal.royalcanin.co.uk/cpd/webinar/
References
Louise O’Dwyer (pictured right) was a highly respected veterinary nurse who dedicated her expertise to developing ECC medicine and teaching others.
She spoke at many congresses across the globe and for a while was a speaker for Improve Veterinary Education before she died in 2019.
The Scholarship is for a place on Improve's ECC training programme, which can be done online or face-to-face. Topics include:
Dr Charlotte French, Head of Business Development UK at Improve, said: “Louise O’Dwyer was a dear friend of ours and we were honoured to have her share her expertise and talents with so many veterinary nurses eager to learn more about ECC.
"This scholarship in her name is our way of thanking her for all that she contributed to the veterinary community and to keep her memory alive by giving someone the wonderful opportunity to gain an achievable postgraduate qualification in an area she was passionate about.”
Applications will be accepted until 31st July 2023: https://subscriptions.improveinternational.com/louise-odwyer-scholarship-entry
The study1 investigated the effects of a weight loss programme on biochemical and immunological profile, blood leptin level, and cardiovascular parameters in a cohort of dogs with naturally occurring obesity, in order to address the effects due to the imbalance of these aspects on the clinical presentation and management of canine obesity.
For the study, eleven obese, but otherwise healthy dogs were included in a six-month weight loss programme, together with a control group of eleven healthy dogs at ideal body condition.
After the six-month weight loss programme, the obese dogs showed clinical improvements on a number of key indicators related to immune function, such as reduced tumour necrosis factor (TNF)-α and interleukin (IL)-6, known to impair insulin action in metabolic tissues but also favour cancer development in humans. Ten out of eleven showing a reduced BCS and no longer classified as obese.
Ten out of eleven dog owners also reported that their dogs were more active and that their quality of life had notably improved.
Hugues du Plessis, Pet Obesity Prevention Manager, at Purina said: “Preventing pet obesity is a major focus at Purina. We not only want to be providing pet owners with information on the benefits of a healthy pet lifestyle, but we also want to help them achieve it. This is why we are working with partner organisations to understand how behavioural science can be used to support owners, from the recognition of an issue, to the changes that will make a difference".
Reference:
The programme includes:
Chris Scudder will also be announcing the successful bids for funding from SAMSoc's new research grant initiative.
Co-organiser Caroline Kisielewicz (pictured right) said: "Despite the trials and tribulations of the ongoing pandemic, we are delighted that the spring SAMSoc meeting has returned this year! We are very excited about the upcoming meeting, which is packed full of great lectures that will stimulate some great talking points. Whilst it won't be the same as being there in person, we hope that everyone will enjoy connecting with colleagues and friends through the virtual world with what promises to be a fantastic event."
The association is also inviting entries now for the next poster/case report competition, details of which can be found at: https://www.samsoc.org/competitions/call-for-spring-2021-poster-entries.
The winning presentation will receive £250, and two runners up will each receive £100.
For the full programme, visit https://www.samsoc.org/meetings/2021-spring-meeting
Registration costs £100 for the day, with a discounted rate at £60 for SAMSoc members (membership costs £29).
To register, visit www.samsoc.org.
A similar scheme will also be run for Australian colleagues wanting to spend time in the UK.
The programme will allow the company's vet nurses to enhance their role internationally and to explore other parts of the world whilst furthering their career.
The programme is open to nurses with over two year's experience, who want to work overseas and then return to their current practice afterwards.
Secondments are also available for staff in support office roles.
Staff will be able to return to their existing roles for up to 12 months, and thereafter a similar role will be made available to them in their region.
Graeme Cramb, Managing Director for CVS Australia, said: “Our vision is to be the veterinary company that most people want to work for and we believe this UK-Australia secondment scheme represents an attractive option for colleagues.
“As the first vet company to offer a UK-Australia secondment scheme, we hope that it enables our colleagues to learn from colleagues in a new territory, further their career and to lead to some exciting cross-pollination of ideas.”
When colleagues express an interest, they will be contacted by CVS recruitment team member to discuss potential opportunities that they can apply for.
They must meet the criteria required to be able to obtain a visa to work in Australia.
Successful applicants will be offered a relocation package and continue to be paid their salary in the UK.
They may also be eligible for the cost of living allowance, paid in Australia.
https://www.careerswithcvs.co.uk/intranet/vacancy/uk-to-australia-secondment-program-4472/18753/description/
DogStem has been shown to be effective, reducing pain and lameness and improving mobility and quality of life for three months to over twelve months following a single injection1,2.
In a prospective, randomised, double-blinded, placebo-controlled trial of DogStem, results showed that2:
TVM highlights how DogStem simplifies the process and reduces the cost of using stem cell therapy in practice because unlike previous therapies, it does not require require a surgical harvesting procedure to be carried out under general anaesthetic.
Helen Harrison, DogStem Technical Vet and Product Manager said: "Osteoarthritis is one of the most common diseases seen in veterinary practices and is challenging to manage.
"Conventional medical treatments typically address the symptoms rather than the underlying pathological processes.
"At the same time, local treatment options that slow progression of osteoarthritis have been limited and surgical interventions aren’t always possible or may be unrewarding.
"We’re delighted to be able to offer vets DogStem®, a stem cell product with a strong evidence base across numerous mobility and quality of life parameters.’
DogStem can be ordered from NVS, or direct from: www.dogstem.co.uk
The study was a randomised controlled trial of client-owned dogs and cats presenting as emergencies and requiring intravenous catheterisation.
Patient signalment and mentation score were recorded.
Patients were randomly allocated to either a swab saturated with vapocoolant spray or a swab saturated with saline applied to the clipped area before intravenous catheterisation.
Indirect application of vapocoolant spray via a swab before catheterisation was not found to significantly reduce the reaction of dogs and cats, nor to improve placement success rates.
The study did demonstrate a significantly greater adverse response to vapocoolant spray application to the skin via a swab when compared with the saline control in canine patients; feline patients demonstrated adverse responses to both vapocoolant spray and saline swabs.
It is unclear if the technique of application used in this study provided sufficient cooling effect to provide the required cryoanaesthesia to influence patient reaction.
The authors say future studies should be used to determine optimal vapocoolant spray application technique in dogs and cats, as well as examine its application in other populations and procedures.
Nicola Di Girolamo, Editor of JSAP concluded: “Pragmatic, adequately-powered, randomised controlled trials like the one presented here are essential to evaluate whether an intervention is not only efficacious in a controlled environment, but also effective during clinical practice.”
Full article: https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13504
Reference
Trinder, R, Humm, K, Phillips, S, and Cole, L (2022) The efficacy of vapocoolant spray for the improved tolerance of catheter pain in emergency patients in dogs Journal of Small Animal Practice, Available at: https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13504
BSAVA Congress, which is open to the whole practice, from reception to the clinical team, will offer free practical drop-in sessions, day-in-the-life dramas, and a bigger wellbeing zone.
There'll be over 120 hours of CPD covering a range of topics such as oncology, veterinary leadership, the RVN’s role, and charity veterinary care.
Paul Higgs, Chair of the Congress Committee, said: “I cannot wait for BSAVA 2023!
"After the successful transformation of BSAVA in our move to Manchester we have been working our socks off to go one better!
"Filled with brilliant speakers, our now trade-mark combination of short, paired lectures with stimulating and inspiring panel discussions, is back in strength.”
Early-bird tickets for BSAVA Congress 2023 are on sale now and BSAVA has brought back one-day only tickets, so if you can’t attend all three days, you have the option to visit on a day that suits you.
https://www.bsavaevents.com/bsavacongress2023/en/page/home
Chair of the Standards Committee, Dr Melissa Donald, said: “We were very aware of the likelihood that both practice staff and clients will increasingly have to isolate over the coming weeks due to direct infection or positive contacts, particularly with the rise in cases amongst school children.
“Added to this, we know there are already workforce pressures across the profession, which will be exacerbated by reduced staffing levels over the Christmas and New Year period.
“We therefore felt it was appropriate to reintroduce these temporary remote prescribing measures at this time to help relieve pressure on practising professionals, and to provide them with the means to continue to look after the health and welfare of their patients in all circumstances.”
As before, the temporary dispensation is subject to the specific guidance found in FAQ4 (www.rcvs.org.uk/covidfaq4), including that veterinary surgeons must be able provide a 24/7 follow-up service involving physical examination, for example where the animal does not improve, or suffers an adverse reaction, or deteriorates, subsequent to the remote prescription of medicines.
The Committee agreed that the position should be reviewed in February 2022 at its next meeting.
The decision was made after Council heard increasing reports that practices have not been keeping records of POM-V parasiticide prescriptions within patient records as has always been required by the VMD.
This created a bit of a problem when the new 'under care' guidance came into force at the start of this month, which requires that veterinary surgeons must perform a physical examination as part of their initial clinical assessment of an animal before prescribing POM-V anti-parasitics.
Failing a record of an existing prescription, that would have meant re-examining large numbers of animals at a time when resources in the profession are already stretched.
RCVS President, Sue Paterson, said: “While it has been both surprising and disappointing to learn of such widespread non-compliance with legislation that has been in place for many years, Council decided to postpone the implementation of this one aspect of our new under care guidance to allow practices additional time to bring their prescribing protocols into line."
The delayed implementation date of 12 January 2024 relates only to the prescription of POM-V anti-parasitics.
The rest of the new under care guidance remains in effect from 1 September 2023
The new guidance will remove the absolute requirement for veterinary surgeons to perform a physical examination before prescribing POM medicines, making it instead a matter for professional judgement.
However, the proposed new guidance also imposes a requirement for veterinary surgeons who do NOT physically examine the animal prior to prescribing to provide a 24/7 follow-up service which includes a physical examination.
Furthermore, the new guidance will state that: "Where the veterinary surgeon is not able to provide this service [the physical exam] themselves, they should arrange for another veterinary service provider to do so. This arrangement should be made before veterinary services are offered and confirmed in writing as part of the conditions of service agreed by the client."
This requirement to provide a physical 24/7 follow-up would appear to safeguard animal welfare and protect against the risk of online-only businesses (in the UK or abroad) with lower overheads cherry-picking the job of prescribing medicines.
It should also protect against veterinary surgeons feeling pressured to prescribe inappropriately, because the new, stricter requirements will make it easier for them to decline to do so.
However, the BVA doesn't agree with the new proposals. It feels that remote prescribing should be delivered under the auspices of a Veterinary Client-Patient-Relationship (VCPR), which, according to the American Veterinary Medical Association, requires a physical examination.
BVA President Malcolm Morley, said: “The changes to ‘under care’ guidance are a watershed moment, so it’s positive to see that they have evolved in response to feedback from the profession. New technology presents exciting opportunities to enhance existing veterinary services and has benefits for practices as well as clients and their animals.
"However, BVA has been very clear that we believe remote prescribing can only be safely delivered where a vet-client-patient relationship has been established.
"This is an internationally recognised concept, and we are disappointed that the RCVS has decided not to embrace it.
“Having voted to implement these changes, it is incumbent upon the RCVS and the profession to scrutinise how they play out.
"At BVA we plan to develop advice and resources to support our members and help them comply with the new guidance and realise any benefits of remote veterinary service provision.’
“It is now vital that a timeframe for a review is quickly put in place, so any negative impacts on animal welfare or the sustainability of veterinary services can be dealt with swiftly.”
Council voted by a majority of 20 to 3 in favour of the changes, which it then decided should come into force between 1st June and 23rd December 2023, subject to a review at the next meeting.
Discuss the propose changes here
Vet Sustain works to inspire and enable veterinary professionals to become leading forces in sustainability and improve the health and wellbeing of animals, people and the environment.
To that end, the company produces tools, training and communications for veterinary professionals centred around its six Veterinary Sustainability Goals (SDGs):
Gudrun Ravetz, Chair and Director of Vet Sustain, said: “We are very pleased to announce IVC Evidensia as a strategic partner of Vet Sustain.
"Veterinary professionals sit at the One Health triumvirate of people, planet and environment every day and working with IVC Evidensia will allow Vet Sustain to continue work on ambitious projects to support veterinary professionals to be active sustainability champions.”
You can find out more about IVC's Sustainability Report here: https://ivcevidensia.com/how-we-work/sustainability/
The overview starts with the CMA noting how it has had significant dealings with many vets and nurses from different practices and acknowledging their dedication and commitment to owners and their animals.
Nevertheless, the CMA has identified various areas of concern about the state of the marketplace:
The CMA says it will publish three further papers in the spring, one sharing its analysis of treatment and pricing data from two large insurance companies, another in which it will lay out its proposed remedies to the concerns it has raised, and a final one analysing the profitability of veterinary businesses.
https://www.gov.uk/cma-cases/veterinary-services-market-for-pets-review#working-papers
The new standards framework sets out the professional values, knowledge, skills and behaviours that are required of awarding organisations and higher education (HE) institutions that provide the curricula, the centres that deliver the courses and their affiliated training practices, as part of the College’s accreditation and re-accreditation processes.
The new framework focuses on six main standards, which apply to awarding organisations/HE institutions, the centres and training practices. The standards are: learning culture; governance and quality; student empowerment; educators and assessors; curricula and assessment; and effective clinical learning.
Julie Dugmore, RCVS Director of Veterinary Nursing, said: "In our previous set of standards there were separate policies and documents for training practices, the centres and the awarding organisations/HE institutions. This now brings all those disparate policies into a unified whole.
"The new standards also place a greater focus on innovation and different types of learning. The previous standards very much assumed that the learning would be done on a face-to-face basis, but we know that, increasingly, student veterinary nurses may be getting the majority of the contact time with their educational institution online and that many institutions have brought in blended learning programmes. These standards recognise this fact and that there are many different ways to learn.
"A greater focus on the student experience is another thing that has really been bolstered in these new standards. For example, we would now be looking for evidence that educational institutions and training practices are providing the support needed for student veterinary nurses to look after their mental health and wellbeing, and that academic and pastoral support is provided to prepare them for independent, reflective practice.
"The new standard will be formally brought into force in January - although for those institutions and organisations that are currently going through the accreditation or re-accreditation process, they can opt to still be assessed via the previous set of standards."
The new standards were drawn-up by a working group comprising VN Council members Alison Carr, Andrea Jefferies and Kathy Kissick, as well as Julie Dugmore.
Veterinary nursing educators were invited to a consultation day in July when they were introduced to the new standards and invited to give feedback.
Kathy Kissick said: "As a former Head of Veterinary Nursing at Myerscough College, I am very glad that we have finally been able to realise and build in the importance of student empowerment into these standards – recognising that veterinary nursing education and training is not just something being done for our students, but something they have a voice and role in shaping.
"Allowing greater choice in the methods and means by which veterinary nursing education is delivered is also a passion of mine and, again, this is something these new standards fully recognise and allow for."
A handbook containing the new accreditation standards will be published on the RCVS website in due course. In the meantime, the documentation is available to download at: https://www.rcvs.org.uk/who-we-are/vn-council/vn-council-meetings/13-november-2019/
Dr Faye Didymus (pictured) and Dr Jackie Hargreaves, who are recipients of the RCVS Sarah Brown Mental Health Research Grant, are exploring how mental health and wellbeing is integrated into the learning paths of SVNs and developing evidence-based recommendations for how mental health education for veterinary nursing students could be enhanced.
To that end, Faye and Jackie are running a webinar to discuss their research findings to date and to offer an opportunity for attendees to contribute to the design and development of the second phase of their research.
Rapinder Newton, MMI Project Lead, said: “Our Sarah Brown Mental Health Research grant has helped to fund six projects looking into various aspects of veterinary mental wellbeing, but this is the first to look specifically into veterinary nurse mental health.
“This is of vital importance, as much of the current research is either targeted towards vets or the vet team as a whole, as opposed to being nurse specific.
"We must do more to ensure that the entire veterinary team feel supported in their work and have the tools to maintain good mental health.
"This kind of research is vital in making positive change for the future, so if you are a current SVN, RVN or help deliver veterinary nursing programmes, then please do get involved.”
The webinar will be taking place online via Zoom on Tuesday 23 April 2024, from 10.30 – 11.30am.
https://www.eventbrite.co.uk/e/a-deep-dive-into-mental-health-education-for-student-veterinary-nurses-tickets-861606587497
Skin diseases and palpable masses are a common presentation in guinea pigs brought for veterinary care2.
However, few studies have thus far looked at the prevalence of spontaneously arising diseases in pet guinea pigs.
"Lumpy bumpy guinea pigs: a retrospective study of 619 biopsy samples of externally palpable masses submitted from pet guinea pigs for histopathology" retrospectively analysed 619 biopsy samples submitted for histopathology from pet guinea pigs that had presented with externally palpable masses.
The purpose was to determine the most common tissue origins of these masses and the most frequent pathological diagnoses, together with signalment data for the most commonly diagnosed lesions.
Of the 619 samples submitted from 493 animals, 54 (8.7%) had arisen from the mammary glands3 and 15 (2.4%) from the thyroid glands, with the remaining 550 (88.9%) involving the skin and subcutis, muscle (n = 1), salivary glands (n = 4), lips (n = 2), ears (n = 4) and peripheral lymph nodes (n = 23).
Forty-seven (7.6%) of the masses were diagnosed as inflammatory in nature, including dermatitis, panniculitis, lymphadenitis, cheilitis, myositis, sialoadenitis, abscess and chronic inflammation with osseous metaplasia.
Non-neoplastic, non-inflammatory lesions accounted for a further 31 (5.0%), namely cysts, hamartomas, hyperplastic lesions, polyps, ectopic bone formation and salivary gland steatosis.
The remainder of the samples were neoplastic in nature (541; 87.4%), with 99 masses classified as epithelial in origin, 347 as mesenchymal, 23 as round cell, five as melanocytic and eight as unclassified malignant neoplasms.
Of these, mesenchymal neoplasms were further subdivided into benign (288) and malignant (59).
Lipomas were the most common neoplasm diagnosed, accounting for 286 of all samples submitted.
Of all 619 samples included in the study, the eight most commonly diagnosed lesions were lipoma (46.2%), trichofolliculoma (12.3%), sarcoma (of various subtypes: 9.5%), inflammation (all sites 7.6%), lymphoma / leukaemia (3.4%), mammary carcinoma (4%), mammary adenoma (3.2%) and thyroid carcinoma (1.5%).
Overall these eight diagnoses accounted for 87.7% of all submissions from the externally palpable masses from the pet guinea pigs submitted for histopathology.
Melanie said: “Guinea pigs are an increasingly popular household pet.
"Skin diseases, including palpable masses, are a common reason for veterinary presentation. But few studies have been published to date that provide information for clinicians about these conditions.
“This study illustrates the importance of neoplasms of the skin and subcutis in pet guinea pigs, with over 87% of the cases analysed having one of eight diagnoses.
"While most of these neoplasms are benign, a substantial minority are malignant and identifying those lesions is especially important in treatment planning.
"Clinicians dealing with pet guinea pigs should also be aware that some externally palpable masses may arise from the thyroid or mammary glands rather than the skin or subcutis, and that male guinea pigs may also develop mammary lesions.”
The paper has been selected as ‘Editor’s Choice’ by the Journal of Comparative Pathology and will be free to access until September on Lumpy, bumpy guinea pigs: a retrospective study of 619 biopsy samples of externally palpable masses submitted from pet guinea pigs for histopathology - ScienceDirect.
Reporting into Chief Veterinary Officer Paul Higgs, Tara will focus on the development of the role of veterinary nurses in CVS.
The role of CVNO at CVS was previously held for a two year term.
CVS says this appointment of a permanent CVNO is to ensure greater continuity in veterinary nurse representation during an important phase of the company's development.
Paul said: “I am excited to welcome Tara into this role to ensure we continue to champion the role of veterinary nurses in CVS and in the profession as a whole.
“Those that know Tara will recognise she is passionate about the role of RVNs and is well positioned to support and influence the importance of the work they do across our company.”
“I am excited to be working alongside Tara as we engage with our teams and continue to foster the right environment to empower nurses and deliver fantastic clinical care in our practices.”
Tara began veterinary work in Norfolk 23 years ago and she joined CVS Group in 2008 as Head Nurse at a practice in Oxford.
She was one of the first CVS Clinical Directors to come from a nursing background and has since moved on to become Regional Director of practices in Norfolk and Suffolk.
The UK-Veterinary Antibiotic Resistance and Sales Surveillance (UK-VARSS) annual report shows that while sales of antibiotics increased slightly by 1.5 mg/kg to 31.0 mg/kg in comparison to the previous year, this was offset by a reduction in use of the more potent critical antibiotics.
UK veterinary antibiotic use in 2019 was the second lowest since the start of regular reporting, and the UK has one of the lowest levels in Europe.
Between 2018 and 2019 there was a 21% drop in of use of Highest Priority Critically Important Antibiotics (HP-CIAs) in food-producing animals, which account for 0.5% of total antibiotic sales. The UK has also seen an overall reduction in the level of resistance in E. coli from healthy pigs at slaughter since 2015 and resistance to HP-CIAs in E. coli is at very low levels.
Peter Borriello, Chief Executive Veterinary Medicines Directorate said: "In the last five years we have worked closely with the farming industry and veterinary profession to achieve huge reductions in use of antibiotics in animals.
"This demonstrates how farmers and vets have been working together to use antibiotics responsibly while safeguarding the health and welfare of our livestock.
"The UK Government will continue to work with industry to focus on infection control, reducing the need to use antibiotics to treat disease and maintain the UK’s world leading standards in animal welfare."
Chief Veterinary Officer Christine Middlemiss said: "I am delighted that the UK continues to lead the way as one of the lowest users of antibiotics in livestock across Europe.
"These findings are testament to the hard work of the UK’s farmers and vets to use antibiotics responsibly in order to tackle antibiotic resistance and protect our most critically important antibiotics in human health, while also reducing the burden of disease in animals."
The stem cells were created as part of a study into feline hypertrophic cardiomyopathy (HCM), which the RVC carried out in association with the Animal Health Trust (AHT), The Beryl Evetts and Robert Luff Animal Welfare Trust (BERLAWT), The Winn Feline Foundation and Boehringer Ingelheim.
The RVC says HCM affects about 15% of the feline population in the UK; translating to over 1 million cats. It is caused by genetic mutations which affect the heart muscle cells.
To date, there are no treatments proven to stop or reverse it, leading to a very poor prognosis for affected cats.
This is partly because a major issue with studying heart diseases at a cellular level is that heart muscle cells do not survive in a laboratory environment. When studying human heart cells, this has been overcome by turning ordinary skin cells into pluripotent stem cells (cells able to turn into any tissue in the body).
These are termed 'induced pluripotent stem cells', or iPSCs. It is then possible to generate heart muscle cells to study from these iPSCs.
The research, carried out by Dr Luke Dutton under the supervision of Professor David Connolly, Dr Jayesh Dudhia and Dr Debbie Guest, as part of his PhD at the RVC in collaboration with AHT, has now identified the conditions required to create iPSCs from domestic cat cells.
While creating iPSCs has been done before in wild cats, the RVC believes that Dr Dutton’s breakthrough in creating iPSCs from domestic cat cells is a world first. It sets the scene for further research into how to turn these iPSCs into heart cells and then, once successful, testing drug therapies that could improve outcomes for cats with HCM.
The researchers say that the translational benefits of this project are potentially very significant, as around 1 in 500 people in the UK have HCM, and the condition manifests in humans in the same way.
If the therapies that researchers test on feline heart cells turn out to be effective, this sets the stage for testing these treatments on humans.
Dr Dutton, author of the study, said: "This is an incredibly exciting project, which is only made possible by the generous funding of the BERLAWT, Boehringer Ingelheim and The Winn Feline Foundation.
"Not only is this study the first reported generation of iPSCs from domestic cats, but these cells can now be used in a novel disease model. This will allow us to study the disease processes present in these cats in ways that have not been possible with the ultimate goal of identifying new therapeutic agents that may slow or even stop the disease process. We would then hope to translate these agents into the feline clinic."
Dr Debbie Guest, Head of Stem Cell Research at the Animal Health Trust, said: "This is the first report on the successful generation of domestic cat iPSCs. These cells not only bring hope to cats suffering from HCM, but allow us to develop new tools to study conditions affecting other tissue types in the future."
Written by members of BSAVA Scientific Committee, together with specialists in internal medicine and neurology, the document explains that there are limited studies showing beneficial effects of CBD, and those that there are need to be interpreted with caution as they involved small sample sizes and used unlicensed products which may have contained other components which could have influenced the results.
The document also explains that legally, CBD products must be prescribed by a veterinary surgeons and not used instead of a medication with proven efficacy.
Caroline Kisielewicz, BSAVA Scientific Committee member and one of the authors of the document said: “Information regarding the effects of cannabinoids on animals is predominantly at the stage of pre-clinical testing of individual substances in mice, rats and guinea pigs. There are limited clinical studies looking at the effects of CBD in dogs, and no reported studies in cats.
"There are many reports describing possible beneficial effects and therapeutic potential in humans, and subsequently pet owners may ask their vet about using cannabinoids to treat veterinary patients. This document aims to provide a broad overview of the available evidence base and legal position in the UK for veterinary team members."
BSAVA President, Ian Ramsey added: "The development of this information is in direct response to an increased interest in the use of CBD to treat cats and dogs. Furthermore, the guidance supports BSAVA’s mission to promote excellence in small animal practice through community, education and science."
The BSAVA position on CBD can be accessed here: https://www.bsavalibrary.com/content/chapter/10.22233/9781910443514.chap8#html_fulltext.
The first is that the College will allow veterinary surgeons and nurses to carry over some of the CPD hours they have accrued in 2019 into 2020, to smoothen the transition to an annual hourly requirement.
Vets will be allowed to carry over 25 hours and VNs 10 hours of accumulated CPD from 2019 through to 2020.
This will apply once, in 2020 only, and is only applicable to vets and VNs who have been CPD-compliant from 2017 to 2019 and have a surplus number of hours to carry over.
Secondly, the College is going to allow vets and VNs to take a six-month 'CPD pause' for planned periods away from work, such as parental leave, and exceptional circumstances, such as serious ill health or unforeseen changes to family responsibilities, without the need to make up the hours when they return to work. This will reduce the burden on vets and VNs returning to work after a break.
RCVS Director of Education, Dr Linda Prescott-Clements said: "We hope that these changes to the CPD policy will support vets and VNs to make the transition to an annual hourly requirement.
"We received a sample of feedback from some members of the veterinary professions regarding the move to annual hourly CPD requirements and these additions have been introduced support members during this transition and to mitigate some of the concerns raised."
For more information about the CPD requirement for both vets and vet nurses, what activities might count as CPD, how to record your CPD and a series of frequently asked questions about CPD please visit our dedicated page: www.rcvs.org.uk/cpd.
Alice and Mariella, who co-authored the book Cracking the Menopause, met with MPs earlier this month to present the goals of their campaign: education for all on the menopause, an end to scaremongering, prescribing women with the correct medication and making HRT affordable and accessible to all.
Vets Now says 88% of its 1800 employees are women, 28% of whom are aged over 40, when they could be perimenopausal, menopausal or postmenopausal.
The company's new app offers its employees video consultations with health experts, health and fitness programmes, and support with mental health and nutrition.
Vet's Now says it's the starting point for a wider menopause support plan being launched later in the year which will include steps to help manage mental wellbeing at work, menopause support hubs and encouraging a culture which talks honestly about menopause.
Laura Black, Head of Health, Safety and Wellbeing, said: “Women over 50 are the fastest growing demographic in the workplace and sadly it’s estimated that almost 900,000 women in the UK have quit their jobs due to the menopause.
“We are committed to creating an understanding workplace for employees going through the perimenopause and menopause and want to make sure they feel supported by us at all times.
“We've launched Peppy to help our colleagues take control of their health and get the answers they need from experts, anytime, anywhere.
"The app is free to access for all employees and their partners.
“We’ve been working hard on formulating a menopause support package for staff over the past couple of years and we’re really proud that we’re one of the first major veterinary businesses to make this step change.
"We’d encourage other businesses in the sector to look at similar plans for their colleagues.”
While the drive to launch Peppy was initially to support the Vets Now Menopause policy, it also provides support for fertility, pregnancy, early parenthood and men’s health.
For more information on Peppy visit www.peppy.health.
Bayer Animal Health has doubled the number of pipettes in its Advocate all-in-one flea, worm and mite spot-on to provide an additional range of six-month treatment packs for cats and dogs. Bayer says the doubling of the number of pipettes in a pack is aimed at providing vets with greater prescribing flexibility and to help improve compliance for owners over a six-month period. Bi-annual vet visits will now give a full year's parasite cover with Advocate. Advocate is now available in three- and six-pipette packs for small and large cats and for medium, large and extra large dogs, and three-pipette packs for small dogs. The product remains the only combined flea, worm and mite spot-on that is licensed for the treatment of A. vasorum in dogs.